Pulse Electronics Corporation C (PULS) Message Board
-
Berg et.al. might end up having to decide that getting something...anything...is better than waiting 20 years..or watching it all go down the toilet. They're not getting any younger...and 'baby needs new shoes'.
-
If $1.29 = 1.43x sales...then 2.5x sales would be around ~ $2.26/sh.
-
I would expect LPTH to be acquired for about 2.5x sales (based on peers I've seen acquired over the years). It's currently trading at 1.42x sales. As long as sales don't significantly decline, and mgt doesn't sell us out cheap...it would be a sizable premium over the current price.
-
Oh no. That's awful.
Sorry I penned that playful jab at her. I actually appreciated her insight most of the time.
What a drag! -
-
I'm confused. They had the money to buy those vessels with cash...but loaned it to DCIX so they could pay their dividend....then we assume more debt from China...but still have no dividend. What kinda company is this?
-
Demi, if that's the way you feel, then you must absolutely love this other laser-related company:
"IRVINE, CA--(Marketwire - Mar 6, 2013) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, announced today that Chief Executive Officer Federico Pignatelli will continue at a symbolic annual cash salary of $1.00 for the year ending December 31, 2013.
Pignatelli stated, "In my continuing effort to align management's interest with the interests of our shareholders, as it should be for every listed Company, and so for BIOLASE, the Board of Directors has accepted my offer to continue to serve as the CEO for a symbolic annual cash salary of $1.00 for 2013. To reiterate what I have said in the past, it simply makes sense to align my interest as a shareholder with that of all shareholders, the ultimate owners of BIOLASE. My goal is for BIOLASE to generate continued growth and improved financial performance. As the Chairman and CEO, I will not benefit unless our shareholders benefit. It remains my firm belief that a CEO's compensation should be tied only to the financial performance of the companies they lead and I invite others to follow my example."
As of December 31, 2012, Pignatelli owned approximately 4.8% of BIOLASE's common shares outstanding on a diluted basis, the vast majority of which he purchased in the open market over time. " -
We've hit the big-time now!
-
.....upgraded by "Jimmy's Auction House".......Jimmy says get your bids in early and buy the whole shootin' match for pennies on the dollar. Highlights include; cushy CEO desk chair with matching ivory-handled back-scratcher, a multitude of un-used beakers, test-tubes and flask previously used as props for tour groups, and a very worn out printing press, previously used for printing stock.
-
"Notice"? What notice?...oh, you mean the stealthy SEC filing.....yeh, I sold that day too. Managed to get $0.40 before the big drop.
-
Guess he hasn't regained consciousness yet.....or perhaps he jumped out the window?
And what about that Falconer guy? Hard to believe that [to hear him tell it] the greatest antibiotic technology ever developed failed to garner ANY interest whatsoever from a single pharma company. They wouldn't even pony up a measely $6.8mil under desperation terms to buy a significant stake in this wondrous technology. Wish we could be privy to the asset/IP firesale terms...so we could see what it ends up going for...if it's sold at all. - Reply to
Its been less than 12 months since the infamous "the next Amgen" statement from Nic
by mulletman99 •Jan 23, 2013 8:49 PMThinking for myself...and with all due respect....YOUR OPINION SUCKS.
Since obviously there were no 'offers on the table'....now Canaccord can review and assist with bancruptcy proceedings.
Bye bye mullethead.............can't say you didn't try to make a difference. But in a rigged game, it's all but impossible. -
...on Nic's cushy office chair and ivory-handled back scratcher...at the asset sale.
- Reply to
Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
by markfive37 •Mar 28, 2013 9:49 PM"Off target effects"...uh-oh, that sounds pretty awful....we all need a cytoskeleton to survive. This stock is gonna get crushed in the morning.
-
Presplit price is now $0.088.
Closing in on a new all-time low.
Are you liking the new shareholder value enhancement? -
...$0.092.
.....and they're now below the $5 threshold required for most institutional investors.
....$.60 away from non-compliance for nasdaq listing.
Can't wait to see what it does when the pricing of the dilution is announced....and when those shares hit the market. -
Like I said before, just because they meet the minimum stock price criterion doesn't mean they comply with all the others. The promise of a nasdaq listing was just an enticer to get people to vote for the split. It will now likely go quietly be the wayside.